Literature DB >> 26885067

Risk factors, management, and prognosis for liver abscess after radical resection of hilar cholangiocarcinoma.

Changxi Zhang1, Tao Li2, Zhiqiang Chen2, Qiangpu Chen3, Xuting Zhi2.   

Abstract

OBJECTIVES: Pyogenic liver abscess (PLA) is a rare but potentially lethal infectious complication after radical surgical resection of hilar cholangiocarcinoma (HC), this study is aimed to identify the risk factors, management and prognosis of PLA after curative surgical resection of HC.
METHODS: Between January 2003 and October 2013, 95 patients who underwent surgical resection of HC at a tertiary center were included in this study. The risk factors pertaining to PLA formation were identified by exact logistic regression.
RESULTS: PLA developed in 8 of 95 patients. The median duration of PLA formation following surgical procedure was 145 days (range, 16-295 days) and the most commonly isolated microorganism was Escherichia coli (4/8). Though most patients who developed PLA after surgery were successfully managed with antibiotics and invasive therapy, the overall survival was statistically poorer than those without PLA formation (median, 16.9 vs. 34.2 months, P=0.048). Univariate analysis revealed that coexisting biliary disorders (37.5% vs. 8.0%, P=0.036), vascular reconstruction (37.5% vs. 9.2%, P=0.041) and margin status (62.5% vs. 21.8%, P=0.023) were associated with PLA formation, whereas only vascular reconstruction (odds ratio (OR), 10.31; 95% confidence interval (CI), 1.03-142.73; P=0.047) and margin status (OR, 8.45; 95% CI, 1.13-109.38; P=0.035) were identified as independent risk factors by multivariate analysis.
CONCLUSIONS: Intraoperative vascular reconstruction and positive margin status pose greater risks for PLA formation after radical resection of HC. For patients with high risk factors, careful follow-up is needed for early detection and management of this infrequent complication.

Entities:  

Keywords:  Pyogenic liver abscess; complications; hilar cholangiocarcinoma; surgical treatment

Year:  2015        PMID: 26885067      PMCID: PMC4723912     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  Hepatic artery reconstruction first for the treatment of hilar cholangiocarcinoma bismuth type IIIB with contralateral arterial invasion: a novel technical strategy.

Authors:  Eduardo de Santibañes; Victoria Ardiles; Fernando A Alvarez; Juan Pekolj; Claudio Brandi; Axel Beskow
Journal:  HPB (Oxford)       Date:  2011-10-23       Impact factor: 3.647

2.  Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not?

Authors:  Masaru Miyazaki; Atsushi Kato; Hiroshi Ito; Fumio Kimura; Hiroaki Shimizu; Masayuki Ohtsuka; Hiroyuki Yoshidome; Hideyuki Yoshitomi; Katsunori Furukawa; Satoshi Nozawa
Journal:  Surgery       Date:  2007-03-23       Impact factor: 3.982

3.  The effect of preoperative biliary drainage on infectious complications after hepatobiliary resection with cholangiojejunostomy.

Authors:  Gen Sugawara; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Yu Takahashi; Daisuke Takara; Masato Nagino
Journal:  Surgery       Date:  2012-10-06       Impact factor: 3.982

4.  Is pyogenic liver abscess associated with recurrent pyogenic cholangitis a distinct clinical entity? A retrospective analysis over a 10-year period in a regional hospital.

Authors:  Siu-tong Law; Kin Kong Li
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-09       Impact factor: 2.566

5.  Liver abscess after liver metastasectomy is a poor prognostic factor in patients with colorectal cancer.

Authors:  Yen-Ning Hsu; Chia-Jen Liu; Jen-Kou Lin; Wei-Shone Chen; Tzu-Chen Lin; Shung-Haur Yang; Jeng-Kai Jiang; Shih-Ching Chang; Yuan-Tzu Lan; Chun-Chi Lin; Chueh-Chuan Yen; Jin-Huang Liu; Cheng-Hwai Tzeng; Hao-Wei Teng
Journal:  J Gastrointest Surg       Date:  2011-07-23       Impact factor: 3.452

6.  Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma.

Authors:  Aakash Chauhan; Michael G House; Henry A Pitt; Attila Nakeeb; Thomas J Howard; Nicholas J Zyromski; C Max Schmidt; Chad G Ball; Keith D Lillemoe
Journal:  HPB (Oxford)       Date:  2010-12-07       Impact factor: 3.647

7.  Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.

Authors:  Sung Gyu Lee; Gi Won Song; Shin Hwang; Tae Yong Ha; Deok Bog Moon; Dong Hwan Jung; Ki Hun Kim; Chul Soo Ahn; Myung Hwan Kim; Sung Koo Lee; Kyu Bo Sung; Gi Young Ko
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-23       Impact factor: 7.027

8.  Late recurrence after surgery for cholangiocarcinoma: implications for follow-up?

Authors:  Harun Thomas; Nigel David Heaton
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-10

9.  Factors associated with treatment failure of percutaneous catheter drainage for pyogenic liver abscess in patients with hepatobiliary-pancreatic cancer.

Authors:  Kuang-Chi Lai; Ken-Sheng Cheng; Long-Bin Jeng; Chi-Chou Huang; Yuan-Ti Lee; Horng-Rong Chang; Chun-Chieh Chen; Shiuan-Chih Chen; Meng-Chih Lee
Journal:  Am J Surg       Date:  2012-07-12       Impact factor: 2.565

Review 10.  Current treatment of pseudomonal infections in the elderly.

Authors:  Georgios Pappas; Kaiti Saplaoura; Matthew E Falagas
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more
  2 in total

1.  Effect of vascular resection for perihilar cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Yong Liu; Guangbing Li; Ziwen Lu; Tao Wang; Yang Yang; Xiaoyu Wang; Jun Liu
Journal:  PeerJ       Date:  2021-09-23       Impact factor: 2.984

2.  Atherosclerosis of the right posterior hepatic artery in a patient with hilar cholangiocarcinoma undergoing left trisectionectomy: a case report of a therapeutic pitfall.

Authors:  Yuichi Goto; Satoki Kojima; Yoriko Nomura; Daisuke Muroya; Syoichiro Arai; Hisamune Sakai; Ryuichi Kawahara; Toru Hisaka; Yoshito Akagi; Hiroyuki Tanaka; Koji Okuda
Journal:  BMC Surg       Date:  2018-09-24       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.